OmniAb Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue growth driven by partner milestones and technology launches, leading to raised full-year guidance. Clinical pipeline progress and expanding AI-enabled platforms position the business for future royalty growth and sustained partner demand.
Fiscal Year 2025
-
Ended 2025 with 107 partners and 407 active programs, launched OmniUltra and xPloration, and saw strong clinical progression. Revenue declined year-over-year but cost controls improved margins, with 2026 guidance projecting a return to growth and a shift toward royalty-driven revenue.
-
OmniUltra, a new transgenic chicken platform, enables discovery of ultra-long CDRH3 antibodies and novel peptides, expanding therapeutic possibilities and attracting strong industry interest. The technology is highly scalable, supports diverse modalities, and is expected to drive new partnerships and revenue opportunities.
-
Q3 saw record partner growth, strong program additions, and the upcoming launch of OmniUltra, expanding into peptide therapeutics. Revenue declined year-over-year, but cost reductions and a $30M private placement strengthened the balance sheet. Guidance was updated as some milestones shifted to 2026.
-
Q2 2025 saw robust partner and program growth, successful launch of the Exploration platform, and continued expansion in clinical-stage assets. Revenue declined year-over-year due to lower milestones, but cost reductions and new technology launches position the business for future growth.
-
Q1 2025 saw revenue growth, reduced expenses, and a narrowed net loss, with strong partner and program expansion. The launch of the Exploration Partner Access Program is expected to diversify revenue streams, though its 2025 impact is not yet included in guidance.
Fiscal Year 2024
-
Double-digit growth in partners and programs, strong Q4 revenue, and new technology launches marked 2024. 2025 guidance anticipates lower reported revenue due to non-cash items, but higher cash receipts and reduced expenses, with continued innovation and pipeline expansion expected.
-
Q3 saw strong growth in partner and program counts, with 86 active partners and 352 programs, despite industry headwinds. Revenue declined year-over-year, but cash position was bolstered by an ATM offering. New technologies and clinical advancements continue to drive momentum.
-
Q2 2024 saw strong revenue growth, record partnership expansion, and robust pipeline progress, with milestone payments expected to drive results in the second half. Cash burn is projected to decrease in 2025 as milestone revenue increases.
-
A leading antibody discovery technology provider highlighted its expanding partner base, innovative multi-species and AI-driven platforms, and robust financial model built on licensing, milestones, and royalties. Growth in clinical programs and new technology launches are expected.